Progress of treatment-free remission in chronic myeloid leukemia

VernacularTitle:慢性粒细胞白血病无治疗缓解的研究进展
Author: Rongrong DU ¹ ; Yanqiu HAN
Author Information

1. 内蒙古医科大学附属医院血液科，呼和浩特　010000
Keywords: Leukemia, myelogenous, chronic; BCR-ABL positive; Tyrosine kinase inhibitor; Treatment-free remission
From: Journal of Leukemia & Lymphoma 2022;31(4):253-256
CountryChina
Language:Chinese
Abstract: The application of tyrosine kinase inhibitor (TKI), a target therapy of chronic myeloid leukemia (CML), has greatly improved the prognosis of patients with CML. However, uninterrupted treatment with TKI affects the quality of life and aggravates the economic burden of patients. Achieving treatment-free remission (TFR) has become the current research direction of CML treatment. This paper reviews the relevant foreign literature on the discontinuation of TKI in recent years.